DrugPatentWatch Database Preview
Onyx Therap Company Profile
What is the competitive landscape for ONYX THERAP, and when can generic versions of ONYX THERAP drugs launch?
ONYX THERAP has one approved drug.
There are eleven US patents protecting ONYX THERAP drugs.
Summary for Onyx Therap
| US Patents: | 11 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Onyx Therap: | See patent lawsuits for Onyx Therap |
Drugs and US Patents for Onyx Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 8,207,125 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | 9,493,582 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 7,491,704 | ➤ Sign Up | ➤ Sign Up | ||||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | 7,737,112 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ONYX THERAP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 60 mg/vial | ➤ Subscribe | 2016-07-20 |
International Patents for Onyx Therap Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Denmark | 1819353 | ➤ Sign Up |
| Japan | 2008509166 | ➤ Sign Up |
| Singapore | 155187 | ➤ Sign Up |
| Canada | 2562411 | ➤ Sign Up |
| Ecuador | SP11011027 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Onyx Therap Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2016 00014 | Denmark | ➤ Sign Up | PRODUCT NAME: CARFILZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/15/1060 20151123 |
| 015 | Luxembourg | ➤ Sign Up | PRODUCT NAME: CARFILZOMIB EVENTUELLEMENT SOUS FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; FIRST REGISTRATION: 20151123 |
| 90013-6 | Sweden | ➤ Sign Up | PRODUCT NAME: CARFILZOMIB OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/15/1060 20151123 |
| 0160008 00189 | Estonia | ➤ Sign Up | PRODUCT NAME: KARFILSOMIIB;REG NO/DATE: EU/1/15/1060 23.11.2015 |
| 2016010,C1781688 | Lithuania | ➤ Sign Up | PRODUCT NAME: KARFILZOMIBAS; REGISTRATION NO/DATE: EU/1/15/1060 20151119 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
